Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology. Currently, pirfenidone and nintedanib are the only FDA-approved drugs for the treatment of IPF and are now the standard of care. This is a significant step in slowing down the progression of the disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimpour, Afshin, Ahir, Manisha, Wang, Min, Jegga, Anil G., Bonnen, Mark D., Eissa, N. Tony, Montesi, Sydney B., Raghu, Ganesh, Ghebre, Yohannes T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712660/
https://www.ncbi.nlm.nih.gov/pubmed/36450789
http://dx.doi.org/10.1038/s41598-022-24985-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712660/
https://www.ncbi.nlm.nih.gov/pubmed/36450789
http://dx.doi.org/10.1038/s41598-022-24985-x

Ejemplares similares